The aim of this study was to determine if cultured porcine vascular smooth muscle cells (pSMCs) that had been maintained on different extracellular matrix proteins had an alteration in their expression of insulin-like growth factor binding protein-5 (IGFBP-5) and their responsiveness to insulin-like growth factor-I (IGF-I). When pSMCs were plated on fibronectin, they synthesized 6.0 ± 1.2-fold more IGFBP-5 than did cells maintained on laminin and type IV collagen. IGF-I increased IGFBP-5 gene expression 3-fold in the cells plated on fibronectin. The addition of an RGD peptide and echistatin to pSMC cultures that had been plated on fibronectin inhibited IGFBP-5 mRNA expression. The addition of an antibody against α2β1 integrin partially reversed the inhibitory effects of laminin and type IV collagen on IGFBP-5 expression. Cells maintained on fibronectin had a 5.0 ± 1.1-fold greater DNA synthesis response to IGF-I compared with those maintained on laminin/type IV collagen, and echistatin significantly inhibited the DNA synthesis response of the fibronectin-maintained cells to IGF-I. The anti-α2β1 antibody partially reversed the inhibitory effect of laminin and type IV collagen on IGF-I-stimulated DNA synthesis. The addition of IGFBP-5 to cultures plated on laminin and type IV collagen significantly increased their response to IGF-I. Atherosclerotic plaques from pig aorta contained abundant fibronectin and had increased IGFBP-5 mRNA (4.5 ± 1.5-fold) compared with tissue from the normal vessel wall that had a low fibronectin content. These results indicate that fibronectin, laminin, and type IV collagen have major effects on IGFBP-5 expression and on IGF-I-stimulated pSMC responses and that these effects are mediated by their respective integrins.

Vascular smooth muscle cells (SMCs) in the media of normal blood vessels are surrounded by a basement membrane that contains type IV collagen and laminin and maintain a differentiated, contractile state characterized by abundant myofilaments and expression of contractile protein isoforms such as α-actin (1). They are quiescent, and the proliferative index is low (1). In contrast, SMCs in the neointima seem to have dedifferentiated. This dedifferentiation includes a marked structural reorganization of the cells, with loss of myofilaments and the formation of an extensive rough endoplasmic reticulum and large Golgi complex (2–4). Their abundance of smooth muscle α-actin decreases, whereas the expression of nonmuscle β- and γ-actin increases (2–4). They synthesize increased amounts of fibronectin and deposit it into their extracellular matrix (ECM). This is termed the synthetic phenotype, and these cells have acquired the ability to proliferate, migrate, and synthesize ECM in response to stimulation by growth factors and cytokines (5). Additionally, cells in the synthetic phenotype constitutively synthesize peptide growth factors, and they have the ability to replicate in the absence of exogenously added mitogens (1).

Extracellular matrix has been shown to play an important role in the modulation of the SMC phenotype in culture (6). Aortic SMCs assume the synthetic phenotype when they are cultured on a fibronectin substratum and will proliferate in response to stimulation by appropriate growth factors. In contrast, if the cells are cultured on laminin and type IV collagen, they will remain in the contractile phenotype. These ECM proteins function by binding to their integrin receptors on the cell surface. Cultured SMCs express the α5β1 and αVβ3 integrins, which bind fibronectin, and the α2β1 integrin, which binds to laminin and several forms of collagen (7).

The growth and differentiation of SMCs are modulated by a number of peptide growth factors, including the IGFs. SMCs in culture have been shown to synthesize IGF-I, and IGF-I stimulates SMC proliferation in an autocrine fashion (8–10). In vivo, IGF-I mRNA and immunoreactive IGF-I are detected in atherosclerotic lesions that develop after injury (11), and the increase in IGF-I mRNA and immunoreactive peptide after balloon denudation injury precedes an associated increase in SMC proliferation (12, 13). IGF-I has also been shown to stimulate SMC migration (14), and this response is mediated by the IGF-I receptors but also requires ligand occupancy of the α2β3 integrin. This ligand occupancy of integrins may play a role in controlling IGF-I responsiveness.

The bioactivities of IGFs are modulated by a group of specific, high affinity IGF binding proteins (IGFBPs) (15). Previous studies have shown that porcine aortic SMCs secrete IGFBP-2, -4, and -5 (16, 17) and that IGFBP-5 can modulate IGF-I-stimulated cell proliferation and migration (18). Because modulation of their phenotypic state alters pSMC responses to peptide growth factors, we determined the ability of specific EM components to regulate IGFBP-5 expression and the responsiveness of these cells to IGF-I.

**EXPERIMENTAL PROCEDURES**

**Materials—** Human fibronectin, type IV collagen, laminin, and echistatin were purchased from Sigma. The peptides GRGESP and
GRGDSP were purchased from Telios Pharmaceuticals Inc. (San Diego, CA). Recombinant human IGF-I was obtained from Bachem Inc. (Torrance, CA). Polyvinylidene difluoride filters were supplied by Millipore Corp. Autoradiographic film was purchased from Eastman Kodak (Rochester, NY). Fetal bovine serum, Dulbecco's modified Eagle's medium, streptomycin, and penicillin were obtained from Gibco Laboratories (Grand Island, NY). A monoclonal antibody against the αsβ1 integrin, was a gift from Dr. Leslie Parise (Department of Pharmacology at UNC-Chapel Hill). Trypsin was obtained from Boehringer Mannheim.

Formaldehyde in PBS for 20 min and then permeabilized with 0.2% for 15 min before the cells were plated on culture dishes.

Maintenance of Porcine Aortic Smooth Muscle Cells (pSMCs) in Culture—pSMCs were obtained from thoracic aortas of pigs using a previously described method (21). They were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 4.5/liter glucose, 100 units/ml penicillin, 100 μg/ml streptomycin, 4 mM glutamine, and 10% fetal bovine serum (complete medium) in 10-cm tissue culture plates (Falcon 3001). The cells were used between passages 2 and 5. To culture the cells on specific ECM proteins, the cells were detached with trypsin/EDTA, trypsin was neutralized with 10% fetal bovine serum, and the cells were rinsed twice with PBS and scraped into SDS sample buffer containing 100 mM dithiothreitol. The protein concentration of each sample was determined by the bicinchoninic acid method.

Expression of Smooth Muscle (SM) α-Actin—SM α–actin was used as a marker for SMC differentiation. Western Immuno blotting analysis—The pSMC cultures were rinsed with PBS and scraped into SDS sample buffer containing 100 mM dithiothreitol. The protein concentration of each sample was determined by the BCA protein assay (Ficoll), and equal amounts of protein (5 μg) per lane were loaded onto 12.5% SDS-polyacrylamide gels. The separated proteins were then transferred to filters (Immobilon PSQ, 0.45-mm pore size, Millipore). The filters were exposed to a monoclonal antibody against smooth muscle α-actin (diluted at 1:1,000 in TBS containing 3% bovine serum albumin) for 14 h at 4 °C. The immunoblots were developed with the enhanced chemiluminescence detection system (Amersham). The immune complexes were detected by chemiluminescence according to the manufacturer's recommendation (Amersham). To determine the fibronectin content in the aortic tissue specimens, the tissue was immediately frozen in liquid nitrogen and then pulverized at −80 °C. The pulverized tissues were transferred into tubes to which lysis buffer containing 20 mM Tris-HCl, pH 7.4, 2% Triton X-100, 10 mM EDTA had been added. The suspension was homogenized for 1 min at 4 °C followed by centrifugation for 5 min at 12,000 × g at 4 °C. The protein concentration in the supernatant was measured and adjusted to be 1 mg/ml by adding 2 × Laemml sample buffer with 0.1 M dithiothreitol. 30 μg of protein was loaded per gel lane, and the proteins in the mixture were separated by 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) in the presence of 0.1 M dithiothreitol. The separated proteins were transferred to Immobilon PSQ filters. Fibronectin was detected using anti-fibronectin polyclonal antibody using a 1:1,000 dilution, and the immune complexes were detected by chemiluminescence according to the procedure cited above.

Immunoprecipitation of IGFBPs—To analyze IGFBP synthesis and secretion into conditioned medium, pSMCs monolayers were exposed to 50 μCi/ml [35S]methionine (5 Ci/mmol) for 8 h in methionine-deficient (2 ×) DMEM. The medium was incubated with a 1:1000 dilution of antibody (model ZBI, Coulter Electronics, Hialeah, FL). For these experiments, the cell number was determined in a particle data counter (Costar 3548) that had been precoated with fibronectin or type IV collagen and laminin with or without IBFBP-5, as described previously. In some experiments, pSMCs were preincubated with echistatin 10-7 M or the P1E6 antibody at a dilution of 1:500 for 15 min before they were plated on the fibronectin or laminin plus type IV collagen. The cultures were maintained for 24 h in serum-free DMEM (with or without the various treatments); then, fresh DMEM (0.1 ml) supplemented with 0.2% human platelet-poor plasma (21, 1 ng/well [3H]thymidine, specific activity, 35 Ci/mmol), and IGF-I (0–20 ng/ml) were added. After 24 h, the plates were placed on ice, washed with ice-cold phosphate-buffered saline twice, and incubated with ice-cold 5% trichloroacetic acid for 10 min. The trichloroacetic acid precipitates were solubilized by adding 0.1 ml of 1% SDS, 0.1 M NaOH overnight, and radioactivity was quantified using a Beckman scintillation counter (Beckman Instruments, Fullerton, CA). For these experiments, the cell number was determined in a particle data counter (model ZBI, Coulter Electronics, Hialeah, FL). For these experiments, the cells were plated at a density of 2 × 104 cells/cm2 in 48-well culture plates (Costar 3548) that had been precoated with fibronectin or type IV collagen and laminin with or without IBFBP-5, as described previously. In some experiments, pSMCs were preincubated with echistatin 10-7 M or the P1E6 antibody at a dilution of 1:500 for 15 min before they were plated on the fibronectin or laminin plus type IV collagen. The cultures were maintained for 24 h in serum-free DMEM (with or without the various treatments); then, fresh DMEM (0.1 ml) supplemented with 0.2% human platelet-poor plasma (21, 1 ng/well [3H]thymidine, specific activity, 35 Ci/mmol), and IGF-I (0–20 ng/ml) were added. After 24 h, the plates were placed on ice, washed with ice-cold phosphate-buffered saline twice, and incubated with ice-cold 5% trichloroacetic acid for 10 min. The trichloroacetic acid precipitates were solubilized by adding 0.1 ml of 1% SDS, 0.1 M NaOH overnight, and radioactivity was quantified using a Beckman scintillation counter (Beckman Instruments, Fullerton, CA). For these experiments, the cell number was determined in a particle data counter (model ZBI, Coulter Electronics, Hialeah, FL). For these experiments, the cells were plated at a density of 2 × 104 cells/cm2 in 24-well plates (Costar 3424). After 24 h, the treatments were added, and the incubation continued for 36 h. The cells were detached with 0.2% trypsin, and the cell number was determined.

RESULTS

Expression of Smooth Muscle (SM) α-Actin—SM α–actin was used as a marker for SMC differentiation. Direct immunofluorescence microscopy showed that the percentage of cells with microfilament bundles that stained intensely for smooth muscle α–actin was greater when the cultures were plated on laminin plus type IV collagen compared with cultures plated on fibronectin (Fig. 1A). Immunoblotting analysis with a monoclonal antibody against smooth muscle α–actin was used to examine the effect of the different substrata on the level of smooth muscle α–actin expression. A single band of 42 kDa was detected using direct immunoblotting. In some experiments, the cells were cultured on fibronectin contain 4.7-fold less smooth muscle α–actin than the cells plated on laminin plus type IV collagen (Fig. 1B). Thus, the cells that were plated on laminin/ type IV collagen maintained this important property of differentiated pSMCs. In contrast, the expression of total α–actin was not decreased in pSMCs plated on fibronectin, as demonstrated using rhodamine-labeled phalloidin (Fig. 1C).

Extracellular Matrix Proteins Regulate IGFBP-5 Synthesis and Secretion—Cultures that were plated on fibronectin or
Changes in Substratum Alters SMC Response to IGF-I

Laminin/type IV collagen had significant differences in the amount of IGFBP-5 that was synthesized and secreted. As shown in Fig. 2A, media obtained from the cells grown on fibronectin had a 1.7-fold \( \pm 0.3 \) \((p < 0.05)\) increase in intact IGFBP-5 compared with cultures maintained on plastic. More important, the amount of IGFBP-5 was 4.0 \( \pm 1.0 \)-fold \((p < 0.01)\) greater than the cells that were plated on laminin/type IV collagen. In contrast, the synthesis of IGFBP-2 was unchanged when cells were cultured using these conditions were compared (Fig. 2B).

To determine if the change of IGFBP-5 synthesis was accompanied by a corresponding change in mRNA, total RNA was isolated from the cells cultured on laminin plus type IV collagen or fibronectin and analyzed by Northern blotting. Compared with cultures maintained on plastic, plating on fibronectin increased IGFBP-5 mRNA levels by 1.5 \( \pm 0.3 \)-fold \((p < 0.05)\) (Fig. 3). In contrast, in the cultures plated on laminin and type IV collagen, the IGFBP-5 mRNA abundance was decreased by 85 \( \pm 6\% \) \((p < 0.01)\) compared with control cultures. The expression of IGFBP-2 mRNA showed no significant changes (Fig. 3).

Influence of ECM on the Ability of IGF-I to Regulate IGFBP-5 mRNA Abundance—As IGFBP-5 gene expression has been shown to be stimulated by IGF-I (17), we examined whether maintaining the cultures on different ECM proteins would alter this cellular response. As shown in Fig. 4, IGF-I increased IGFBP-5 mRNA abundance in the pSMCs that had been plated on either fibronectin or laminin plus type IV collagen. Although cells maintained in laminin/type IV collagen responded to IGF-I with an increase in IGFBP-5 expression \((6.1 \pm 1.0\) to 41 \( \pm 5.0\), arbitrary units \(p < 0.01)\), the absolute level of IGFBP-5 mRNA was substantially below that detected in cultures that had been maintained on fibronectin \((54 \pm 4.0\) to 140 \( \pm 15\), arbitrary units \(p < 0.01)\).

Cell Replication Assays of pSMCs Cultured on Different ECM Substrata—pSMCs cultured on different substrata were also analyzed for their ability to synthesize DNA in response to IGF-I. The results showed that the response to IGF-I was significantly greater \((560 \pm 84\%\) compared with 112 \( \pm 12\%, p < 0.01)\) for cells plated on fibronectin compared with cells plated on laminin plus type IV collagen (Fig. 5). These data are consistent with the responses in Fig. 4 showing that cells plated on type IV collagen retain some capacity to respond to IGF-I, but the absolute level that can be attained is decreased significantly. The addition of IGFBP-5 to cultures that were plated on laminin and type IV collagen resulted in marked potentiation of the cellular response to IGF-I. In contrast, the addition of IGFBP-5 to cultures plated on fibronectin did not alter the cellular response to IGF-I significantly.

The Effect of Different ECM Proteins Is Mediated by Their Respective Integrins—As pSMCs have been reported to express \( \alpha_\beta_1, \alpha_\beta_2, \) and \( \alpha_\beta_3 \) integrins, we examined whether blocking ligand binding to some of these integrins would influence IGFBP-5 expression. Following a 30-min exposure to synthetic peptides or to anti-integrin antibodies, the cells were plated on fibronectin or laminin/type IV collagen dishes. The adherence of pSMC to the substratum was unaffected by preincubating with the
these reagents at the given concentrations. After a 24-h incubation, IGFBP-5 mRNA abundance was quantified. The synthetic RGD peptide that binds $\alpha_5\beta_1$ and echistatin blocked the fibronectin-induced change in IGFBP-5 expression (Fig. 6). A control RGE peptide had no effect. The inhibition of IGFBP-5 expression that was induced by laminin and type IV collagen was partially reversed by the antibody against $\alpha_2\beta_1$ integrin. These data indicate that binding of these matrix proteins to their respective integrins is an important step in their ability to modulate IGFBP-5 expression. To determine if these integrins were also involved in modulating the DNA synthesis response to IGF-I, a similar experiment was conducted using $[3H]$thymidine incorporation as an index of IGF-I action. As shown in Fig. 7, exposure of pSMC plated on fibronectin to echistatin attenuated the cellular DNA synthesis response to IGF-I. In contrast, the P1E6 antibody partially reversed the inhibitory effect of ligand occupancy of $\alpha_2\beta_1$ on IGF-I-stimulated replication. To determine if altering ligand occupancy of these integrins would alter the cellular growth response to IGF-I, cell number was determined using a similar experimental design. Quiescent pSMC cultures that were plated on fibronectin increased their final cell number by $61 \pm 6\%$ in response to 20 ng/ml of IGF-I. The addition of echistatin (10$^{-7}$ M) decreased this response to $32 \pm 4\%$. The cells plated on laminin/type IV collagen increased $11 \pm 2.1\%$, and those that were exposed to the P1E6 antibody increased $18 \pm 2.1\%$.

Atherosclerotic Lesions Contain Abundant Fibronectin and Have Greater IGFBP-5 mRNA Expression Compared with Normal Aorta—To determine if the SMCs in lesions express more IGFBP-5 than cells in the normal arterial wall, atherosclerotic

---

**Fig. 3.** Effects of ECM substratum on the steady-state levels of IGFBP-5 and IGFBP-2 mRNA. A, total RNA was isolated from SMCs that had been maintained on plastic dishes (lanes 1 and 4), on fibronectin (lanes 2 and 5), or on laminin plus type IV collagen (lanes 3 and 6) for 48 (lanes 1–3) or 96 h (lanes 4–6). Total RNA was isolated and subjected to Northern blotting. RNAs were detected with specific cDNA probes for human IGFBP-5 and -2. Upper panel, autoradiography of IGFBP-5 and -2 mRNAs; middle panel, 28 S and 18 S RNA ethidium bromide staining; lower panels, PhosphorImage analyses. This experiment was repeated three times with similar results.

**Fig. 4.** IGF-I regulates the mRNA expression of IGFBP-5 in pSMCs cultured on fibronectin (lanes 1–3) or laminin plus type IV collagen (lanes 4–6). pSMCs were plated on these ECM proteins and maintained for 24 h; then, IGF-I was added, and the incubation was continued for another 24 h. Total RNA was isolated from the cells and subjected to Northern blotting using the cDNA probe for human IGFBP-5. Lanes 1 and 4, no IGF-I; lanes 2 and 5, IGF-I (50 ng/ml); lanes 3 and 6, IGF-I (100 ng/ml). Upper panel, autoradiograph of IGFBP-5 mRNA; middle panel, autoradiograph of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA; lower panel, PhosphorImage analysis of IGFBP-5 mRNA. Three experiments were conducted with similar results.
lesions that were diet induced were extracted, and their RNA was analyzed by Northern blotting. The results showed that lesions contain 4.5 ± 1.5-fold (p < 0.05) (n = 4 separate animals) more IGFBP-5 mRNA compared with normal subendothelial tissue. A representative experiment is shown in Fig. 8A.

The fibronectin content in these tissue specimens was also determined. The results show that a 5.9-fold greater amount of fibronectin was detected in the lesion tissue compared with normal aorta (Fig. 8B).

**DISCUSSION**

In normal blood vessels, SMCs are attached to a basement membrane that contains type IV collagen and laminin. Within the arterial wall, most SMCs are maintained in a quiescent state and express contractile protein isoforms. However, in response to vascular injury, SMCs alter their phenotype and are stimulated to proliferate and migrate. This phenotypic transition from the contractile to the synthetic state is accompanied by enhanced expression of specific matrix proteins such as fibronectin (9). The phenotypic transition can be modulated in vitro by changing the composition of ECM substratum (6).

Aortic SMCs have been reported to convert to the synthetic phenotype when cultured on a fibronectin substratum, and, if maintained on fibronectin, they will proliferate if they are also exposed to appropriate growth factors. In contrast, if the cells are cultured on laminin plus type IV collagen, early passage (e.g., <p>5) cells can be maintained in a nonproliferative state for 1 week (6). This was confirmed in our study by showing abundant expression of smooth muscle α-actin and an increased number of microfilament bundles that stained for α-actin. In contrast, cells that were plated and maintained on fibronectin had much lower α-actin content. Based on these results, we believe that the in vitro modulation of the pSMC phenotype was similar to that previously reported by others (6).

A major finding in the present study is that, compared with cells cultured on laminin and type IV collagen, pSMCs cultured on fibronectin synthesize and release more IGFBP-5. The increase in IGFBP-5 synthesis is associated with increased IGFBP-5 mRNA expression. The effect becomes manifest between the 2nd and 4th days after changing the ECM substratum. The effect is specific for IGFBP-5 as IGFBP-2 protein and mRNA levels were unaltered by the ECM proteins. This suggests that expression of this gene may be an important component of phenotype transition. Because IGFBP-5 has been shown to potentiate the cellular growth-promoting effect of IGF-I (23), this may be relevant to the observation noted by several groups that synthetic phenotype cells are more responsive to growth factors (9, 24–26). This conclusion is strengthened by our observation that the addition of IGFBP-5 to cultures plated on laminin/type IV collagen enhanced their DNA synthesis response to IGF-I, suggesting that the enhanced expression of IGFBP-5 in the fibronectin-exposed cultures may...
be an important component of this enhanced replication response to IGF-I. These changes were also reflected in the IGFBP-5 synthesis response to IGF-I. We had previously shown that IGF-I induced a 6-fold increase in IGFBP-5 mRNA (17); therefore, we analyzed the responses of pSMC that expressed each phenotype. Although pSMC plated on fibronectin had a greater increase in IGFBP-5 expression in response to IGF-I, cultures maintained in the nonproliferative phenotype still showed some IGF-I responsiveness. There are two possible interpretations of this result. First, fibronectin is acting to directly stimulate basal (non-IGF-I dependent) IGFBP-5 expression and to enhance the response to IGF-I. This conclusion is supported by our data showing that peptide antagonists of ligand binding to αvβ3 and αvβ5 can inhibit IGFBP-5 expression. Second, it is also possible that a low percentage of cells have not been maintained in the nonproliferative phenotype and, therefore, have acquired IGF-I responsiveness. In either case, it seems that the synthetic phenotype cells are more responsive to IGF-I. In addition to modulating the IGFBP-5 synthesis response to IGF-I, plating pSMC on different substrata modulated the DNA synthesis response. This effect also seemed to be ECM protein-mediated as cells that were plated on laminin/type IV collagen had a reduced DNA synthesis response to IGF-I compared with the response of cells plated on fibronectin.

To test the hypothesis that the effects of these ECM molecules were mediated by their respective integrins, pSMCs were incubated with an antibody or peptides that bind to and block integrin ligand occupancy. The adherence of pSMCs to matrix-coated plates was unaffected by preincubating the cells with either RGD peptide or the antibody at the indicated concentrations. These results indicate that the effect of fibronectin on IGFBP-5 expression is mediated by αvβ1 and αvβ3 integrins, as both the RGD peptide and echistatin, a disintegrin that has been shown to block fibronectin binding to αvβ3 integrin, inhibited the induction of IGFBP-5 by fibronectin. Because we have previously shown that vitronectin binding to αvβ3 is required for pSMC to migrate in response to IGF-I and because echistatin also blocked the IGFBP-5 response to IGF-I, it is likely that αvβ3 occupancy by fibronectin is also augmenting this response. In contrast to fibronectin, exposure to type IV collagen/laminin resulted in maintenance of IGFBP-5 expression at a low level. When occupancy of the αvβ3 integrin was blocked with the P1E6 antibody, this inhibition of IGFBP-5 expression could be partially reversed. This strongly suggests that αvβ3 integrin ligand occupancy is acting to inhibit IGFBP-5 expression. Additionally, the effects of these ECM proteins on IGF-I-stimulated DNA synthesis seem to be integrin mediated as blocking binding to αvβ3 or αvβ5 partially reversed the effects of these ligands on IGF-I-stimulated replication. Taken together, these results support the conclusion that the effects of the ECM proteins used in this study are integrin mediated and that integrin ligand occupancy modulates IGF-I responsiveness. Therefore, the capacity of this growth factor to stimulate pSMC replication is directly related to the context in which the growth factor signal is presented to its cognate receptor.

IGFs exert multiple effects on target cells that are mediated by the IGF-I receptor on the cell surface. IGF-I has been shown to stimulate proliferation as well as migration of pSMCs (14). In addition to the direct influences on the cells, IGF-I exposure is also required for the full activity of several other growth factors or cytokines. IGF-I has been shown to enhance the effects of platelet-derived growth factor (27), thrombin (28), and angiotensin II (29) on cultured SMCs. Selective inhibition of IGF-I binding to its receptor with anti-IGF-I antibody results in marked reduction in the mitogenic response to thrombin (28) and angiotensin II (29). In vivo, IGF-I mRNA and immunoreactive IGF-I are detected in intimal lesions that develop in humans (11). IGF-I mRNA and immunoreactive IGF-I levels both increase severalfold after balloon denudation injury in rats, and these increases are temporally preceded by an increase in SMC proliferation (12, 13). Thus, IGF-I may be important for SMC proliferation and migration in vivo and may play an important role in the development of atherosclerotic lesions.

Our findings suggest that variables such as enhanced binding of fibronectin to αvβ3 or increased binding of type IV colla-
ogen to αβ3 may also modulate responsiveness of pSMC to other growth factors. Recent studies have shown that ligand occupancy of the αβ3 integrin functions to regulate growth factor actions. Platelet-derived growth factor (30) and IGF-I (14) have a diminished capacity to stimulate cell migration if ligand occupancy of this integrin is attenuated. Similarly blocking integrin or growth factor receptor-associated signaling pathways, such as induction of phosphatidylinositol-3 kinase and inositol phosphate-3 formation, results in inhibition of migration (30). The mechanistic explanations that have been proposed to explain these observations include coactivation of signal transduction elements by growth factor tyrosine kinase receptors and integrins such as insulin receptor substrate-1 (31) or calmodulin-II kinase (32, 33) and, in the case of fibroblast growth factor, direct activation of the receptor kinase activity by integrin occupancy (34). Our findings suggest that the αβ3 occupancy is activating IGF-I signaling, resulting in not only enhanced migration but also in enhanced replication. In contrast, no studies have been reported to date that blocking ligand occupancy of αβ3 will enhance growth factor actions. In the case of platelet-derived growth factor, occupancy of this integrin was stated to enhance the SMC migration response (35). Therefore, further studies that are directed toward elucidating the mechanism by which αβ3 occupancy is inhibiting IGF-I actions are warranted.

IGF bioactivities are modified by a family of six high affinity IGFBPs. Among them, IGFBP-5 has the unique property of adhering tightly to ECM (23). When associated with ECM, the affinity of IGFBP-5 is lowered 8-fold. This affinity shift results in a more favorable equilibrium between IGF-I bound to ECM-associated IGFBP-5 and to the IGF-I receptor, and this is associated with an enhanced cellular DNA synthesis response to IGF-I. Additionally, the amount of ECM-associated IGFBP-5 has been shown to be related to the degree of enhancement of the cellular growth response (23). This hypothesis was confirmed by our results showing that the addition of IGFBP-5 to cultures that were plated on laminin and type IV collagen significantly increased the cellular response to IGF-I. Therefore, factors such as the induction of IGFBP-5 synthesis by fibronectin could result in further enhancement of the cellular responses to IGF-I. Similarly, an increase in the affinity of αβ3 for its ligands, which occurs following IGF-I binding to its receptor (14), may contribute to this response.

These observations may have some relevance to the development of atherosclerotic lesions in vivo. This study demonstrated that atherosclerotic lesions contain more IGFBP-5 mRNA compared with comparable amounts of normal vessel wall. Although several cell types exist in atherosclerotic plaques, SMCs are the predominant cell type (5). Similarly, as the SMCs within lesions have assumed the synthetic phenotype and because fibronectin is much more abundant, it is possible that the increase observed in IGFBP-5 mRNA in atherosclerotic lesions (36, it is possible that this change also contributes to enhanced IGFBP-5 expression. Furthermore, because other ECM proteins that bind to αβ3, such as thrombospondin and osteopontin, are abundant in lesions and have the potential to act through αβ3 to alter the smooth muscle cell phenotype and responsiveness (37, 38), it will be of interest to determine their effects on IGF-I and IGFBP-5 actions.

Acknowledgment—We thank George Mosley for help in preparing this manuscript.

REFERENCES

1. Thyberg, J., Hedin, U., Sjöholm, M., Palmberg, L., and Bottger, B. A. (1990) Artherosclerosis 10, 966–990
2. Ross, R., Wight, T. N., Strandness, E., and Thiele, B. (1984) Am. J. Pathol. 114, 9–23
3. Moss, P. R. L., Campbell, G. C., Wang, Z. L., and Campbell, J. H. (1995) Lab. Invest. 53, 556–562
4. Moss, P. R. L., Campbell, G. R., and Campbell, J. H. (1986) Artherosclerosis 8, 664–669
5. Ross, R. (1993) Nature 362, 801–809
6. Hedin, U., Bottger, B. A., Forsberg, E. Johansson, S., and Thyberg, J. (1989) J. Cell. Biol. 109, 305–317
7. Assilian, R. K., and Marcantonio, E. E. (1990) J. Clin. Invest. 89, 1043–1049
8. Clemmons, D. R. (1985) Circ. Res. 56, 418–426
9. Benedetti, K. E., Arnaquist, H. L., and Norstedt, G. (1990) J. Endocrinol. 125, 381–386
10. Delafontaine, P., Lou, H., and Alexander, R. W. (1991) Hypertension 18, 722–747
11. Grant, M. B., Wargovich, T. J., Ellis, E. A., Caballer, O. S., Mansour, M., and Pepine, C. J. (1994) Circulation 89, 1511–1517
12. Cerek, B., Fishbein, M. C., Forrester, J. S., Helfant, R. H., and Fagin, J. A. (1990) Circ. Res. 66, 1755–1760
13. Khorosandi, M. J., Fagin, J. A., Giannella-Neto, D., Forrester, J. S., and Cerek, B. (1992) J. Clin. Invest. 90, 1926–1931
14. Jones, J. I., Prevette, T., Jones, A. A., and Clemmons, D. R. (1996) Endocrinology 136, 4168–4173
15. Jones, J. I., and Clemmons, D. R. (1995) Endocr. Rev. 16, 3–34
16. Coffick, W. H., Gockerman, A., and Clemmons, D. R. (1993) J. Cell Physiol. 157, 52–69
17. Duan, C., Hawes, S. B., Prevette, T., and Clemmons, D. R. (1996) J. Biol. Chem. 271, 4280–4288
18. Inaiz, Y., Busby, W. H., Smith, C. E., Clarke, J. B., Horvitz, G. D., Boes, C., and Clemmons, D. R. (1997) J. Clin. Invest. 100, 2596–2605
19. Gockerman, A., Prevette, T., Jones, J. I., and Clemmons, D. R. (1995) J. Biol. Chem. 270, 9596–9603
20. Bourner, M. J., Busby, W. H., Jr., Siegel, N. R., Krivi, G. G., McCusker, R. H., and Clemmons, D. R. (1994) J. Cell. Biochem. 54, 215–226
21. Ross, R. (1971) J. Cell Biol. 50, 172–186
22. Nichols, T. C., Hellinger, D. A., Tate, D. A., Reddick, R. L., Read, M. S., Koch, G. G., Brinkhaus, K. M., and Griggs, T. R. (1990) Arteriosclerosis 10, 449–461
23. Jones, J. I., Gockerman, A., Busby, W. H., Camacho-Hubner, C., and Clemmons, D. R. (1993) J. Cell. Biol. 121, 679–687
24. Clyman, R. I., Mauray, F., and Kramer, R. H. (1992) Exp. Cell Res. 200, 272–284
25. Dartsch, P. C., Voisaid, R., Bauridel, G., Hotling, B., and Betz, E. (1999) Atherosclerosis 16, 62–75
26. Chambly-Campbell, J. H., Campbell, G. R., and Ross, R. (1990) J. Cell Biol. 89, 379–383
27. Clemmons, D. R. (1985) Endocrinology 117, 77–83
28. Delafontaine, P., Anwar, A., Lou, H., and Ku, L. (1996) J. Clin. Invest. 97, 339–345
29. Delafontaine, P., and Lou, H. (1993) J. Biol. Chem. 268, 16866–16870
30. Bilato, C., Curtis, K. A., Monticone, R. E., Pauly, R. R., White, A. J., and Crow, M. T. (1997) J. Clin. Invest. 100, 693–704
31. Vuoril, K., and Hoshi, H. (1994) Science 266, 1576–1578
32. Pauly, R. R., Bilato, C., Sollott, S. J., Monticone, R., Kelly, P. T., Lakatta, E. G., and Crow, M. T. (1995) Circulation 91, 1107–1115
33. Bilato, C., Pauly, R. R., Monticone, R., Gorelick-Feldman, D., Gluzband, Y. A., Sollott, S. J., Ziman, B., Lakatta, E. G., and Crow, M. T. (1995) J. Clin. Invest. 96, 1905–1915
34. Miyamoto, S., Terao, H., Goto, K., and Yamada, K. S. (1996) J. Cell Biol. 133, 1635–1642
35. Skinner, M. D., Rains, E. W., and Ross, R. (1994) Am. J. Pathol. 145, 170–176
36. Hoshiga, A., Smith, L. L., Giachelli, C. M., and Schwartz, S. M. (1995) Circ. Res. 77, 1129–1135
37. Liaw, L., Skinner, M. D., Rains, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., and Giachelli, C. M. (1995) J. Clin. Invest. 95, 713–724
38. Giachelli, C. M., Rae, N., Amedoa, M., Denhardt, D. T., Alpers, C. E., and Schwartz, S. M. (1993) J. Clin. Invest. 92, 1686–1696
39. Camacho-Hubner, C., Busby, W. H., McCusker, R. H., Wright, G., and Clemmons, D. R. (1992) J. Biol. Chem. 267, 11949–11956